Corbus Pharmaceuticals
CRBP
82 hedge funds and large institutions have $27.3M invested in Corbus Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 20 reducing their positions, and 17 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 20
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.01% less ownership
Funds ownership: 1.19% → 1.19% (-0.01%)
4% less funds holding
Funds holding: 85 → 82 (-3)
13% less call options, than puts
Call options by funds: $290K | Put options by funds: $332K
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
40% less capital invested
Capital invested by funds: $45.6M → $27.3M (-$18.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$761K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$275K |
| 3 |
Renaissance Technologies
New York
|
+$222K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$166K |
| 5 |
D.E. Shaw & Co
New York
|
+$127K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$589K |
| 2 |
Morgan Stanley
New York
|
-$531K |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$234K |
| 4 |
HF
HRT Financial
New York
|
-$179K |
| 5 |
VF
Virtu Financial
New York
|
-$164K |
CRBP Hedge Fund Activity: Q4 2021 in Review
82 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q4 2021, worth a combined $27.3M — down 40% from $45.6M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CRBP and 14 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 24 added.
The largest buyer was Citadel Advisors, adding an estimated $761K. The largest seller was Bank of America, cutting an estimated $589K.
- 82 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q4 2021, down from 85 in Q3 2021.
- Funds reported $27.3M of Corbus Pharmaceuticals stock for Q4 2021, down 40% quarter-over-quarter.
- 14 funds opened new Corbus Pharmaceuticals positions in Q4 2021 and 17 closed out, a net change of -3 holders.
- The largest Corbus Pharmaceuticals buyer in Q4 2021 was Citadel Advisors, an estimated $761K added.
- The largest Corbus Pharmaceuticals seller in Q4 2021 was Bank of America, an estimated $589K sold.
Based on aggregated 13F filings for Q4 2021.